VCG
BIO icon

Vantage Consulting Group’s Bio-Rad Laboratories Class A BIO Stock Holding History

Vantage Consulting Group’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-103
Closed -$60K – 287
2020
Q4 		$60K Buy
+103
New +$58.7K ﹤0.01% 380

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Vantage Consulting Group's BIO Position: Q1 2021 in Review

Vantage Consulting Group sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2021, closing a stake of 103 shares — an estimated $60K sold.

Vantage Consulting Group first reported a position in BIO in Q4 2020 and held it in 1 quarter. The position peaked at $60K in Q4 2020. 491 funds tracked by Wall St. Rank hold BIO as of Q1 2021.

  • Vantage Consulting Group reported no remaining Bio-Rad Laboratories Class A position as of Q1 2021 after selling out during the quarter.
  • Vantage Consulting Group sold 103 Bio-Rad Laboratories Class A shares in Q1 2021, an estimated $60K.
  • Vantage Consulting Group first reported a position in Bio-Rad Laboratories Class A in Q4 2020 and held it in 1 quarter.
  • Vantage Consulting Group's Bio-Rad Laboratories Class A position peaked at $60K in Q4 2020.
  • 491 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2021.

Based on Vantage Consulting Group's 13F filing for Q1 2021, filed 14 May 2021.